Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more
Livzon Pharmaceutical Group Inc (LVZPF) - Net Assets
Latest net assets as of September 2025: $15.36 Billion USD
Based on the latest financial reports, Livzon Pharmaceutical Group Inc (LVZPF) has net assets worth $15.36 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.53 Billion) and total liabilities ($9.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.36 Billion |
| % of Total Assets | 62.63% |
| Annual Growth Rate | 13.28% |
| 5-Year Change | 9.28% |
| 10-Year Change | 209.9% |
| Growth Volatility | 21.12 |
Livzon Pharmaceutical Group Inc - Net Assets Trend (1992–2024)
This chart illustrates how Livzon Pharmaceutical Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Livzon Pharmaceutical Group Inc (1992–2024)
The table below shows the annual net assets of Livzon Pharmaceutical Group Inc from 1992 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.91 Billion | +0.94% |
| 2023-12-31 | $14.77 Billion | -1.14% |
| 2022-12-31 | $14.94 Billion | +4.37% |
| 2021-12-31 | $14.31 Billion | +4.92% |
| 2020-12-31 | $13.64 Billion | +11.12% |
| 2019-12-31 | $12.28 Billion | +4.47% |
| 2018-12-31 | $11.75 Billion | +4.60% |
| 2017-12-31 | $11.23 Billion | +58.09% |
| 2016-12-31 | $7.11 Billion | +47.73% |
| 2015-12-31 | $4.81 Billion | +17.82% |
| 2014-12-31 | $4.08 Billion | +13.26% |
| 2013-12-31 | $3.60 Billion | +13.35% |
| 2012-12-31 | $3.18 Billion | +5.60% |
| 2011-12-31 | $3.01 Billion | +14.11% |
| 2010-12-31 | $2.64 Billion | +18.59% |
| 2009-12-31 | $2.23 Billion | +21.31% |
| 2008-12-31 | $1.83 Billion | -7.86% |
| 2007-12-31 | $1.99 Billion | +44.42% |
| 2006-12-31 | $1.38 Billion | +11.31% |
| 2005-12-31 | $1.24 Billion | +5.68% |
| 2004-12-31 | $1.17 Billion | -0.22% |
| 2003-12-31 | $1.17 Billion | +4.00% |
| 2002-12-31 | $1.13 Billion | +8.93% |
| 2001-12-31 | $1.04 Billion | +2.96% |
| 2000-12-31 | $1.01 Billion | +3.40% |
| 1999-12-31 | $973.90 Million | -8.68% |
| 1998-12-31 | $1.07 Billion | +2.87% |
| 1997-12-31 | $1.04 Billion | +34.70% |
| 1996-12-31 | $769.62 Million | +16.20% |
| 1995-12-31 | $662.32 Million | +6.23% |
| 1994-12-31 | $623.47 Million | +14.05% |
| 1993-12-31 | $546.67 Million | +98.39% |
| 1992-12-31 | $275.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Livzon Pharmaceutical Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19753.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.76 Billion | 84.84% |
| Common Stock | $911.35 Million | 6.57% |
| Other Components | $1.19 Billion | 8.58% |
| Total Equity | $13.86 Billion | 100.00% |
Livzon Pharmaceutical Group Inc Competitors by Market Cap
The table below lists competitors of Livzon Pharmaceutical Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Merchants Corporation Depository Shares
NASDAQ:FRMEP
|
$1.58 Billion |
|
Shaanxi Aerospace Power Hi-Tech Co Ltd
SHG:600343
|
$1.58 Billion |
|
Highwealth Construction Corp
TW:2542
|
$1.58 Billion |
|
CSG Holding Co Ltd
SHE:000012
|
$1.58 Billion |
|
Hangcha Group Co Ltd
SHG:603298
|
$1.58 Billion |
|
NextVision Stabilized Systems, Ltd.
PINK:NXSNF
|
$1.58 Billion |
|
Enerflex Ltd.
NYSE:EFXT
|
$1.58 Billion |
|
LendingClub Corp
NYSE:LC
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Livzon Pharmaceutical Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,042,495,302 to 13,862,334,189, a change of -180,161,113 (-1.3%).
- Net income of 2,061,095,803 contributed positively to equity growth.
- Dividend payments of 1,340,306,595 reduced retained earnings.
- Share repurchases of 858,562,382 reduced equity.
- Other comprehensive income decreased equity by 1,180,423,171.
- Other factors increased equity by 1,138,035,232.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.06 Billion | +14.87% |
| Dividends Paid | $1.34 Billion | -9.67% |
| Share Repurchases | $858.56 Million | -6.19% |
| Other Comprehensive Income | $-1.18 Billion | -8.52% |
| Other Changes | $1.14 Billion | +8.21% |
| Total Change | $- | -1.28% |
Book Value vs Market Value Analysis
This analysis compares Livzon Pharmaceutical Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.23x to 0.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | $0.34 | $3.43 | x |
| 1994-12-31 | $0.75 | $3.43 | x |
| 1995-12-31 | $0.80 | $3.43 | x |
| 1996-12-31 | $0.90 | $3.43 | x |
| 1997-12-31 | $1.14 | $3.43 | x |
| 1998-12-31 | $1.16 | $3.43 | x |
| 1999-12-31 | $1.03 | $3.43 | x |
| 2000-12-31 | $1.05 | $3.43 | x |
| 2001-12-31 | $1.05 | $3.43 | x |
| 2002-12-31 | $1.09 | $3.43 | x |
| 2003-12-31 | $1.19 | $3.43 | x |
| 2004-12-31 | $1.30 | $3.43 | x |
| 2005-12-31 | $1.38 | $3.43 | x |
| 2006-12-31 | $1.53 | $3.43 | x |
| 2007-12-31 | $2.22 | $3.43 | x |
| 2008-12-31 | $2.03 | $3.43 | x |
| 2009-12-31 | $2.52 | $3.43 | x |
| 2010-12-31 | $2.97 | $3.43 | x |
| 2011-12-31 | $3.38 | $3.43 | x |
| 2012-12-31 | $3.55 | $3.43 | x |
| 2013-12-31 | $3.96 | $3.43 | x |
| 2014-12-31 | $4.37 | $3.43 | x |
| 2015-12-31 | $5.08 | $3.43 | x |
| 2016-12-31 | $7.41 | $3.43 | x |
| 2017-12-31 | $11.60 | $3.43 | x |
| 2018-12-31 | $11.42 | $3.43 | x |
| 2019-12-31 | $11.95 | $3.43 | x |
| 2020-12-31 | $12.90 | $3.43 | x |
| 2021-12-31 | $13.92 | $3.43 | x |
| 2022-12-31 | $14.83 | $3.43 | x |
| 2023-12-31 | $15.09 | $3.43 | x |
| 2024-12-31 | $15.07 | $3.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Livzon Pharmaceutical Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.87%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.45%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.76x
- Recent ROE (14.87%) is above the historical average (12.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 21.50% | 8.47% | 1.18x | 2.16x | $31.69 Million |
| 1994 | 16.35% | 16.85% | 0.69x | 1.41x | $39.28 Million |
| 1995 | 12.20% | 11.74% | 0.62x | 1.69x | $14.44 Million |
| 1996 | 11.03% | 11.29% | 0.55x | 1.78x | $7.59 Million |
| 1997 | 4.34% | 5.25% | 0.54x | 1.52x | $-56.22 Million |
| 1998 | 4.01% | 4.54% | 0.58x | 1.53x | $-61.03 Million |
| 1999 | 0.18% | 0.15% | 0.73x | 1.73x | $-88.55 Million |
| 2000 | 1.13% | 0.88% | 0.74x | 1.73x | $-81.22 Million |
| 2001 | 5.48% | 3.61% | 0.83x | 1.82x | $-41.51 Million |
| 2002 | 6.52% | 3.87% | 0.86x | 1.96x | $-33.00 Million |
| 2003 | 8.83% | 5.09% | 0.85x | 2.04x | $-12.26 Million |
| 2004 | 10.89% | 7.98% | 0.71x | 1.93x | $10.09 Million |
| 2005 | 8.96% | 6.63% | 0.75x | 1.80x | $-12.55 Million |
| 2006 | 10.39% | 9.21% | 0.61x | 1.84x | $5.20 Million |
| 2007 | 26.17% | 29.09% | 0.59x | 1.52x | $314.18 Million |
| 2008 | 2.93% | 2.53% | 0.70x | 1.64x | $-125.78 Million |
| 2009 | 22.41% | 18.55% | 0.83x | 1.45x | $266.67 Million |
| 2010 | 16.61% | 15.34% | 0.74x | 1.45x | $166.44 Million |
| 2011 | 12.64% | 11.36% | 0.69x | 1.62x | $75.05 Million |
| 2012 | 14.68% | 11.20% | 0.70x | 1.87x | $140.87 Million |
| 2013 | 14.58% | 10.56% | 0.70x | 1.96x | $153.04 Million |
| 2014 | 13.96% | 9.31% | 0.76x | 1.98x | $146.33 Million |
| 2015 | 14.33% | 9.40% | 0.82x | 1.86x | $188.02 Million |
| 2016 | 12.06% | 10.25% | 0.73x | 1.62x | $133.75 Million |
| 2017 | 41.11% | 51.91% | 0.54x | 1.48x | $3.35 Billion |
| 2018 | 10.16% | 12.21% | 0.51x | 1.64x | $16.98 Million |
| 2019 | 11.67% | 13.88% | 0.52x | 1.61x | $186.20 Million |
| 2020 | 14.16% | 16.30% | 0.51x | 1.70x | $504.19 Million |
| 2021 | 13.66% | 14.72% | 0.54x | 1.72x | $475.31 Million |
| 2022 | 13.76% | 15.12% | 0.51x | 1.79x | $521.81 Million |
| 2023 | 13.91% | 15.72% | 0.50x | 1.78x | $549.40 Million |
| 2024 | 14.87% | 17.45% | 0.48x | 1.76x | $674.86 Million |
Industry Comparison
This section compares Livzon Pharmaceutical Group Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Livzon Pharmaceutical Group Inc (LVZPF) | $15.36 Billion | 21.50% | 0.60x | $1.58 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |